<DOC>
	<DOCNO>NCT01749514</DOCNO>
	<brief_summary>The purpose study evaluate effect ACE-536 anemia patient low intermediate-1 risk MDS .</brief_summary>
	<brief_title>Study ACE-536 Treatment Anemia Patients With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Key 1 . Documented diagnosis idiopathic/de novo MDS nonproliferative chronic myelomonocytic leukemia ( CMML ) , accord WHO criteria ( white blood count , 13,000/uL ) , meet International Prognostic Scoring System ( IPSS ) classification low intermediate1 risk disease determine microscopic standard cytogenetic analysis bone marrow peripheral complete blood count ( CBC ) obtain screen . 2 . Anemia define : 1 . Mean hemoglobin concentration &lt; 10.0 g/dL 2 measurement ( one perform within one day prior Cycle 1 Day 1 perform 728 day prior Cycle 1 Day 1 , influence RBC transfusion within 7 day measurement ) nontransfusion dependent patient ( define receive &lt; 4 unit RBCs within 8 week prior Cycle 1 Day 1 ) , OR 2 . Transfusion dependent , define receive ≥ 4 unit RBCs within 8 week prior Cycle 1 Day 1 . 3 . Serum erythropoietin level prior erythropoiesisstimulating agent ( ESA ) treatment : Dose escalation cohort expansion cohort 1 patient : Serum erythropoietin level &gt; 500 U/L , OR , ≤ 500 U/L , patient nonresponsive , refractory , intolerant erythropoiesisstimulating agent ( ESAs ) , ESAs contraindicate unavailable . Expansion cohort 2 patient : If patient RS+ ( define ≥ 15 % ring sideroblasts bone marrow ) , prior ESA treatment serum erythropoietin level ≤ 200 U/L . If patient RS ( define &lt; 15 % ring sideroblasts bone marrow ) , prior ESA treatment serum erythropoietin level allow . 4 . No alternative treatment option , per applicable MDS guideline , available and/or appropriate patient , discretion investigator . 5 . ECOG performance status 0 , 1 , 2 ( related anemia ) . 6 . Adequate renal ( creatinine ≤ 2 x upper limit normal [ ULN ] ) hepatic ( total bilirubin &lt; 2 x ULN AST ALT &lt; 3 x ULN ) function . 7 . Adequate transferrin saturation ( ≥ 15 % ) , ferritin ( ≥ 50 µg/L ) , folate ( ≥ 4.5 nmol/L [ ≥ 2.0 µg/L ] ) vitamin B12 ( ≥ 148 pmol/L [ ≥ 200 pg/mL ] ) screening ( supplementation retest screen acceptable ) . 8 . Females child bear potential ( define sexually mature woman undergone hysterectomy bilateral oophorectomy , naturally postmenopausal ≥ 24 consecutive month ) must negative urine blood pregnancy test prior enrollment use adequate birth control method ( abstinence , oral contraceptive , barrier method spermicide , surgical sterilization ) study participation 12 week follow last dose ACE536 . Males must agree use latex condom sexual contact female childbearing potential participating study 12 week follow last dose ACE 536 , even undergone successful vasectomy . Patients must counsel concern measure use prevent pregnancy potential toxicity prior first dose ACE536 . 9 . Patients able adhere study visit schedule , understand comply protocol requirement . 10 . Patients understand able provide write informed consent . Key 1 . Prior treatment azacitidine decitabine . 2 . Treatment within 28 day prior Cycle 1 Day 1 : ) Erythropoiesis stimulate agent ( ESA ) , ii ) Granulocyte colonystimulating factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) , iii ) Lenalidomide . 3 . Iron chelation therapy initiate within 56 day prior Cycle 1 Day 1 . 4 . Treatment another investigational drug device , approve therapy investigational use ≤ 28 day prior Cycle 1 Day 1 , halflife previous product know , within 5 time halflife prior Cycle 1 Day 1 , whichever longer . 5 . Major surgery within 28 day prior Cycle 1 Day 1 . Patients must completely recover previous surgery prior Cycle 1 Day 1 . 6 . Platelet count &lt; 30 x 109/L . 7 . Any active infection require parenteral antibiotic therapy within 28 day prior Cycle 1 Day 1 oral antibiotic within 14 day Cycle 1 Day 1 . 8 . History stroke , deep venous thrombosis ( DVT ) arterial embolism within 6 month prior Cycle 1 Day 1 . 9 . Known positive human immunodeficiency virus ( HIV ) , active infectious hepatitis B ( HBV ) active infectious hepatitis C ( HCV ) . 10 . Any malignancy MDS remission and/or require systemic therapy include radiation , chemotherapy , hormonal therapy surgery , within last year prior Cycle 1 Day 1 . 11 . Uncontrolled hypertension , define systolic blood pressure ( BP ) ≥ 150 mm Hg diastolic BP ≥ 100 mm Hg . 12 . Pregnant lactating female . 13 . History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational drug . 14 . Any condition specifically note , judgment investigator , would preclude patient participate study . 15 . Transfusion event within 7 day prior Cycle 1 Day 1 . 16 . Prior treatment sotatercept ( ACE011 ) ACE536 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>